# MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell Carcinoma

> **NCT07054307** · PHASE1 · RECRUITING · sponsor: **Jiyan Liu** · enrollment: 10 (estimated)

## Conditions studied

- Penile Cancer

## Interventions

- **DRUG:** MRG003
- **DRUG:** HX008

## Key facts

- **NCT ID:** NCT07054307
- **Lead sponsor:** Jiyan Liu
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-12
- **Primary completion:** 2026-07-30
- **Final completion:** 2030-07-30
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-04-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07054307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07054307, "MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07054307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*